{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:50:55Z","timestamp":1791337855876,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40263-020-00703-x","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T17:02:32Z","timestamp":1580317352000},"page":"207-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Pitolisant: A Review in Narcolepsy with or without Cataplexy"],"prefix":"10.1007","volume":"34","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"43","key":"703_CR1","first-page":"1","volume":"18","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Management of narcolepsy. Curr Treat Options Neurol. 2016;18(43):1\u201313.","journal-title":"Curr Treat Options Neurol."},{"key":"703_CR2","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1212\/WNL.58.12.1826","volume":"58","author":"MM Ohayon","year":"2002","unstructured":"Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the general European population. Neurology. 2002;58:1826\u201333.","journal-title":"Neurology."},{"issue":"5","key":"703_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/14656566.2018.1561861","volume":"20","author":"S de Biase","year":"2019","unstructured":"de Biase S, Gigli GL, Valente M. Important decisions in choosing the pharmacotherapy for narcoleptics. Expert Opin Pharmacother. 2019;20(5):483\u20136.","journal-title":"Expert Opin Pharmacother."},{"issue":"5","key":"703_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40263-016-0337-4","volume":"30","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30(5):369\u201379.","journal-title":"CNS Drugs."},{"issue":"16","key":"703_CR5","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s40265-013-0127-y","volume":"73","author":"AK De la Herr\u00e1n-Arita","year":"2013","unstructured":"De la Herr\u00e1n-Arita AK, Garc\u00eda-Garc\u00eda F. Current and emerging options for the drug treatment of narcolepsy. Drugs. 2013;73(16):1771\u201381.","journal-title":"Drugs."},{"key":"703_CR6","first-page":"4654","volume":"19","author":"FP Busard\u00f2","year":"2015","unstructured":"Busard\u00f2 FP, Kyriakou C, Napoletano S, et al. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome. Eur Rev Med Pharmacol Sci. 2015;19:4654\u201363.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"703_CR7","doi-asserted-by":"crossref","unstructured":"Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist\/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther. 2007;320(1):365\u201375.","DOI":"10.1124\/jpet.106.111039"},{"issue":"1","key":"703_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nbd.2007.12.003","volume":"30","author":"JS Lin","year":"2008","unstructured":"Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: studies in orexin\u2212\/\u2212 mice and patients. Neurobiol Dis. 2008;30(1):74\u201383.","journal-title":"Neurobiol Dis."},{"key":"703_CR9","unstructured":"Bioprojet Pharma. Wakix (pitolisant): summary of product characteristics. 2019. http:\/\/www.ema.europa.eu\/. Accessed 8 Jan 2020."},{"key":"703_CR10","unstructured":"Harmony Biosciences. WAKIX\u00ae (pitolisant) tablets, for oral use: US prescribing information. 2019. http:\/\/www.accessdata.fda.gov\/. Accessed 8 Jan 2020."},{"key":"703_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.neuropharm.2018.10.028","volume":"144","author":"DM Riddy","year":"2019","unstructured":"Riddy DM, Cook AE, Shackleford DM, et al. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. Neuropharmacology. 2019;144:244\u201355.","journal-title":"Neuropharmacology."},{"key":"703_CR12","unstructured":"Committee for Medicinal Products for Human Use. Wakix (pitolisant) public assessment report. 2015. http:\/\/www.ema.europa.eu\/. Accessed 8 Jan 2020."},{"issue":"11","key":"703_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsz174","volume":"42","author":"Y Dauvilliers","year":"2019","unstructured":"Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long-term use of pitolisant to treat narcolepsy: HARMONY III study. Sleep. 2019;42(11):1\u201311.","journal-title":"Sleep."},{"key":"703_CR14","doi-asserted-by":"crossref","unstructured":"Ligneau X, Shah RR, Berrebi-Bertrand I, et al. Nonclinical cardiovascular safety of pitolisant: comparing international conference on harmonization S7B and comprehensive in vitro pro-arrhythmia assay initiative studies. Br J Pharmacol. 2017;174(23):4449\u201363.","DOI":"10.1111\/bph.14047"},{"key":"703_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.sleep.2017.01.002","volume":"33","author":"M Kollb-Sielecka","year":"2017","unstructured":"Kollb-Sielecka M, Demolis P, Emmerich J, et al. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. Sleep Med. 2017;33:125\u20139.","journal-title":"Sleep Med."},{"issue":"4","key":"703_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/j.1476-5381.2011.01286.x","volume":"163","author":"JC Schwartz","year":"2011","unstructured":"Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713\u201321.","journal-title":"Br J Pharmacol."},{"issue":"3","key":"703_CR17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/bph.12149","volume":"169","author":"M Uguen","year":"2013","unstructured":"Uguen M, Perrin D, Belliard S, et al. Preclinical evaluation of the abuse potential of pitolisant, a histamine H3 receptor inverse agonist\/antagonist compared with modafinil. Br J Pharmacol. 2013;169(3):632\u201344.","journal-title":"Br J Pharmacol."},{"key":"703_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejphar.2019.02.019","volume":"851","author":"B Huyts","year":"2019","unstructured":"Huyts B, Brabant C, Tirelli E. Pitolisant and intravenous cocaine self-administration in mice. Eur J Pharmacol. 2019;851:63\u20138.","journal-title":"Eur J Pharmacol."},{"issue":"Suppl 1","key":"703_CR19","doi-asserted-by":"publisher","first-page":"A243","DOI":"10.1093\/sleep\/zsz067.610","volume":"42","author":"JM Dayno","year":"2019","unstructured":"Dayno JM, Scart-Gr\u00e8s C, Robert P, et al. Evaluation of abuse potential of the narcolepsy medication pitolisant [abstract no. 0612]. Sleep. 2019;42(Suppl 1):A243\u20134.","journal-title":"Sleep."},{"key":"703_CR20","unstructured":"Scart-Gr\u00e8s C, Setnik B, Lecomte JM, et al. Randomized, single dose, double-blind, 4-way crossover study determining the abuse potential of pitolisant compared to phentermine and placebo, in healthy, non-dependent recreational stimulant users [abstract no. P282 and poster]. J Sleep Res. 2018;27(Suppl 1):219\u201320."},{"issue":"11","key":"703_CR21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","volume":"12","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068\u201375.","journal-title":"Lancet Neurol."},{"issue":"3","key":"703_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1474-4422(16)30333-7","volume":"16","author":"Z Szakacs","year":"2017","unstructured":"Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200\u20137.","journal-title":"Lancet Neurol."},{"issue":"Suppl 1","key":"703_CR23","doi-asserted-by":"publisher","first-page":"A244","DOI":"10.1093\/sleep\/zsz067.612","volume":"42","author":"C Scart-Gr\u00e8s","year":"2019","unstructured":"Scart-Gr\u00e8s C, Momah C, Roy M, et al. Safety and tolerability of pitolisant in the treatment of adults with narcolepsy: integrated data from clinical studies [abstract no. 0614]. Sleep. 2019;42(Suppl 1):A244\u20135.","journal-title":"Sleep."},{"issue":"8","key":"703_CR24","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.sleep.2012.06.006","volume":"13","author":"P Jennum","year":"2012","unstructured":"Jennum P, Ibsen R, Petersen ER, et al. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13(8):1086\u201393.","journal-title":"Sleep Med."},{"key":"703_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/j.1365-2869.2001.00234.x","volume":"10","author":"E Daniels","year":"2001","unstructured":"Daniels E, King MA, Smith IE, et al. Health-related quality of life in narcolepsy. J Sleep Res. 2001;10:75\u201381.","journal-title":"J Sleep Res."},{"issue":"8","key":"703_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/14656566.2017.1323877","volume":"18","author":"U Kallweit","year":"2017","unstructured":"Kallweit U, Bassetti C. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother. 2017;18(8):809\u201317.","journal-title":"Expert Opin Pharmacother."},{"key":"703_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","volume":"16","author":"MJ Thorpy","year":"2015","unstructured":"Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16:9\u201318.","journal-title":"Sleep Med."},{"key":"703_CR28","unstructured":"National Institute for Health and Care Excellence. Narcolepsy with or without cataplexy in adults: pitolisant. 2017. http:\/\/www.nice.org.uk\/. Accessed 8 Jan 2020."},{"key":"703_CR29","doi-asserted-by":"crossref","unstructured":"Billiard M, Dauvilliers Y, Dolenc-Gro\u0161elj L, et al. Management of narcolepsy in adults. In: Gilhus NE, Barnes MP, Brainin M, editors. European handbook of neurological management. p. 513\u201328.","DOI":"10.1002\/9781444328394.ch38"},{"key":"703_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11325-019-01894-4","author":"C Franceschini","year":"2019","unstructured":"Franceschini C, Pizza F, Antelmi E, et al. Narcolepsy treatment: pharmacological and behavioral strategies in adults and children. Sleep Breath. 2019. https:\/\/doi.org\/10.1007\/s11325-019-01894-4.","journal-title":"Sleep Breath."},{"key":"703_CR31","unstructured":"Jazz Pharmaceuticals Inc. XYREM\u00ae (sodium oxybate) oral solution, CIII: US prescribing information. 2018. http:\/\/www.accessdata.fda.gov\/. Accessed 8 Jan 2020."},{"key":"703_CR32","unstructured":"Teva Pharmaceuticals USA Inc. PROVIGIL\u00ae (modafinil) tablets, for oral use, C-IV: US prescribing information. 2015. http:\/\/www.accessdata.fda.gov\/. Accessed 8 Jan 2020."},{"issue":"7","key":"703_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.5665\/sleep.4810","volume":"38","author":"A van der Heide","year":"2015","unstructured":"van der Heide A, van Schie MKM, Lammers GJ, et al. Comparing treatment effect measurements in narcolepsy: the Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test. Sleep. 2015;38(7):1051\u20138.","journal-title":"Sleep."},{"issue":"Suppl 1","key":"703_CR34","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/j.sleep.2017.11.544","volume":"40","author":"P Lehert","year":"2017","unstructured":"Lehert P. Epworth sleepiness scale ESS: determination of a minimum clinically relevant difference [abstract]. Sleep Med. 2017;40(Suppl 1):e186\u20137.","journal-title":"Sleep Med."},{"issue":"12","key":"703_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/sleep\/zsy185","volume":"41","author":"P Lehert","year":"2018","unstructured":"Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018;41(12):1\u201313.","journal-title":"Sleep."},{"key":"703_CR36","unstructured":"Plazzi G, Kallweit U, Causs\u00e9 C, et al. A 5-year post-authorization safety study (PASS) relative to Wakix\u00ae (pitolisant) use and its long-term safety in narcolepsy with or without cataplexy in routine medical practice [abstract no. P198]. J Sleep Res. 2018;27(Suppl 1):180."},{"key":"703_CR37","unstructured":"UCB Pharma S.A. Xyrem (sodium oxybate) 500\u00a0mg\/mL oral solution: summary of product characteristics. 2015. http:\/\/www.ema.europa.eu\/. Accessed 8 Jan 2020."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00703-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00703-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00703-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:54:41Z","timestamp":1611795281000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00703-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00703-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"29 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yvette Lamb is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}